Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways.

TitleAbrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways.
Publication TypeJournal Article
Year of Publication2013
AuthorsZhang L, You J, Sidhu J, Tejpal N, Ganachari M, Skelton ST, Kloc M, Li XC, Ghobrial RM
JournalTransplantation
Volume96
Issue9
Pagination782-90
Date Published2013 Nov 15
Abstract

Current immunosuppressive regimens fail to avert chronic rejection (CR) of transplanted organs; however, selective targeting of actin-cytoskeletal regulators decreases T-cell motility and abrogates CR in rat model system. Administration of mutated class I major histocompatibility complex molecules or selective targeting of the RhoA pathway, which controls T-cell cytoskeletal activity, using Y27632 (a selective Rock1 inhibitor) resulted in reduced T-cell infiltration and abrogation of CR as judged from the neointimal index (13.9±19.7 vs. 45±37.5; P<0.001) and the number of affected vessels (30% vs. 60%; P<0.01). Here, we examined the role of mammalian target of rapamycin (mTOR) pathway in inhibition of CR.

DOI10.3389/fnins.2013.00151
Alternate JournalTransplantation